Building H.O.U.S.E (Healthy Outcomes Using a Supportive Environment): Exploring the Role of Affordable and Inclusive Housing for LGBTQIA+ Older Adults

Little is known about how permanent, inclusive, affordable, and supportive long‐term housing may affect the health of low‐income lesbian, gay, bisexual, transgender, queer, intersex, asexual and/or another identity (LGBTQIA+) older adults. Focus group interviews were conducted with 21 older adults to explore the lived experiences and potential health benefits of living in a new LGBTQIA+‐welcoming senior housing. Participants reported that moving into the housing was associated with benefits for health and well‐being, especially for psychological health. Community, social support, and in‐house services were particularly important. However, the combined nature of LGBTQIA+‐welcoming and older adult only housing evoked mixed feelings. Appropriate and accessible housing solutions are essential for LGBTQIA+ older adults and may help address health disparities for these populations

Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York

Purpose New York State (NYS) is an epicenter of the SARS-CoV-2 pandemic in the United States. Reliable estimates of cumulative incidence in the population are critical to tracking the extent of transmission and informing policies. Methods We conducted a statewide seroprevalence study in a 15,101 patron convenience sample at 99 grocery stores in 26 counties throughout NYS. SARS-CoV-2 cumulative incidence was estimated from antibody reactivity by first poststratification weighting and then adjusting by antibody test characteristics. The percent diagnosed was estimated by dividing the number of diagnoses by the number of estimated infection-experienced adults. Results Based on 1887 of 15,101 (12.5%) reactive results, estimated cumulative incidence through March 29 was 14.0% (95% confidence interval [CI]: 13.3%–14.7%), corresponding to 2,139,300 (95% CI: 2,035,800–2,242,800) infection-experienced adults. Cumulative incidence was highest in New York City 22.7% (95% CI: 21.5%–24.0%) and higher among Hispanic/Latino (29.2%), non-Hispanic black/African American (20.2%), and non-Hispanic Asian (12.4%) than non-Hispanic white adults (8.1%, P \u3c .0001). An estimated 8.9% (95% CI: 8.4%–9.3%) of infections in NYS were diagnosed, with diagnosis highest among adults aged 55 years or older (11.3%, 95% CI: 10.4%–12.2%). Conclusions From the largest U.S. serosurvey to date, we estimated \u3e2 million adult New York residents were infected through late March, with substantial disparities, although cumulative incidence remained less than herd immunity thresholds. Monitoring, testing, and contact tracing remain essential public health strategies

The Moderating Capacity of Racial Identity Between Perceived Discrimination and Psychological Well‐Being Over Time Among African American Youth

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/88122/1/j.1467-8624.2011.01651.x.pd

2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents.

BACKGROUND: A 1-year follow-up, polymer-free metallic stent coated with biolimus-A9 followed by 1-month dual antiplatelet therapy is safer and more effective than a bare-metal stent (BMS) for patients with high risk of bleeding. OBJECTIVES: This study analyzed 2-year outcomes to determine whether these benefits are maintained. METHODS: In a prospective, multicenter, double-blind trial, we randomized 2,466 high bleeding risk patients to receive a drug-coated stent (DCS) or a BMS followed by 1-month dual antiplatelet therapy. The primary safety endpoint was a composite of cardiac death, myocardial infarction, or stent thrombosis. The primary efficacy endpoint was clinically driven target lesion revascularization. RESULTS: At 2 years, the primary safety endpoint had occurred in 147 DCS and 180 BMS patients (15.3%) (hazard ratio: 0.80; 95% confidence interval: 0.64 to 0.99; p = 0.039). Clinically driven target lesion revascularization occurred for 77 DCS and 136 BMS patients (12.0%) (hazard ratio: 0.54; 95% confidence interval: 0.41 to 0.72; p 75 years, anemia, raised plasma creatinine, and planned long-term anticoagulation. Correlates of the primary safety endpoint were age, anemia, congestive heart failure, multivessel disease, number of stents implanted, and use of a BMS rather than a DCS. CONCLUSIONS: Safety and efficacy benefits of DCS over BMS were maintained for 2 years in high bleeding risk patients. Rates of major bleeding and coronary thrombotic events were no different and were associated with a substantial and comparable mortality risk. (A Prospective Randomized Comparison of the BioFreedom Biolimus A9 Drug Coated Stent Versus the Gazelle Bare Metal Stent in Patients With High Risk of Bleeding [LEADERS FREE]; NCT01623180)

Target gene analyses of 39 amelogenesis imperfecta kindreds

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90297/1/EOS_857_sm_FigsS1-S3.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/90297/2/j.1600-0722.2011.00857.x.pd

Zinc modulates mitogenic responses of human lymphocytes by affecting structures influenced by cytochalasin B

We have previously reported that zinc affects the mitogenic process in an age-dependent fashion when added to lectin-stimulated lymphocytes. The present studies demonstrate an additional selective effect of zinc when added to Con A-activated lymphocytes plus pharmacologic agents known to affect the cytoskeleton or the permeability of the plasma membrane. Specifically, addition of zinc did not modulate the dose-dependent activities of Ca2+ ionophore A23187, nigericin, or colchicine demonstrating that the immunologic effects of zinc do not involve modification of Ca2+ or K+ fluxes, or microtubule formation. By contrast, a consistent and reproducible shift in the cytochalasin B dose-response curve of lymphocytes stimulated by Con A was observed when zinc was added. These data indicate that the effect of zinc on immune functions may be operating through cytochalasin B-sensitive subcellular structures, most likely microfilaments.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/23189/1/0000116.pd